本帖最后由 老马 于 2012-1-13 21:20 编辑 % p" z( z7 ~6 K8 f
- d7 `. u, F9 Z* R
爱必妥和阿瓦斯丁的比较- v2 o8 X3 a( Q
" I: y& g4 D. Y# ^$ \http://cancergrace.org/lung/2008/08/30/bms099-os-neg/% S4 r. j7 j3 q
2 F7 ~3 H3 S9 s1 {+ `
4 y; E7 r) N5 A- S( f$ s M
http://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/
5 ]! |! O+ Z9 o6 r6 A7 g5 {& i==================================================9 W' Z8 p# D# ?/ g: J
Overall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
" [. y) J/ q7 U) V9 b8 H/ J3 \Patients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.
" G5 G7 H) i: k9 i0 ?& R L3 XResults: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (~62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported., O* O* M" b' q& x* [
|